S3V Vascular Technologies Unlisted shares are attracting investor are attracting investor attention as India’s healthcare investment landscape shifts from hospitals towards MedTech .strong domestic demand , import substitution, export potential, and high entry barriers are making medical device companies an attractive long term opportunity.
While India has no major listed pure-play MedTech companies,S3V Vascular Technologies is emerging as a notable unlisted player , building an Integrated portfolio of cardiovascular and neurovascular devices and positioning itself to benefit from the country’s rapidly expanding medical device industry.
Why Private Equity Is Shifting to MedTech
Private equity has traditionally invested in hospitals, with India’s hospital sector attracting nearly US$6 billion in annual investments over the past five years through around 120 healthcare transactions each year. Investor exits have also surged from US$1.2 billion to US$6.2 billion in FY25, reflecting growing confidence in the healthcare sector.
However, investor focus is increasingly shifting toward MedTech. Since 2017, India has recorded 59 private equity deals in medical devices, with deal activity rising 3.3x compared to pre-COVID levels. The sector’s share of total healthcare deal value has nearly doubled from 6% to 11%.
Rising Healthcare Spending Supports MedTech Growth
Global healthcare spending continues to rise, with Current Healthcare Expenditure (CHE) increasing from 6.5% of global GDP in 2017 to 7.0% in 2022. Governments fund nearly 76% of healthcare spending globally, while India contributes only 39%, indicating significant room for future healthcare investment.
The growing burden of non-communicable diseases (NCDs) is a key growth driver. These diseases account for 74% of global deaths, with cardiovascular diseases responsible for nearly one-third of all deaths. Around 80% of cardiovascular deaths occur in low- and middle-income countries, highlighting the growing need for affordable and advanced medical technologies.
India’s Rising Cardiovascular Burden Creates a Strong Growth Opportunity for S3V vascular Technologies
Cardiovascular diseases account for 28% of all deaths in India, with 10.8 million new cases and 2.9 million deaths reported in 2021. As healthcare demand rises, India’s hospital infrastructure has expanded from 43,500 hospitals in 2019 to around 70,000 in 2024, while private hospitals are expected to add 24,000 new beds over the next 3–5 years.
The number of cath labs has also increased from 650 in 2015 to around 2,500 in 2023, with 200–250 new cath labs expected to be added every year. This growing cardiovascular infrastructure is expected to drive demand for vascular intervention devices, creating a long-term growth opportunity for companies such as S3V Vascular Technologies.
Global and Indian Medical Device Markets Offer Strong Growth Potential
The global medical device market was valued at US$518 billion in 2024 and is projected to reach US$667 billion by 2029. Cardiovascular devices remain the largest segment, accounting for around 12.5% of the global market.
India is one of the fastest-growing medical device markets, expected to expand from US$16.4 billion in 2023 to US$60.2 billion by 2030 at a 20.4% CAGR. Medical device exports are also projected to increase from US$3.4 billion in 2023 to nearly US$18 billion by 2030. Within this, the implant segment, where S3V Vascular Technologies operates, is expected to grow from US$1.5 billion to over US$5.4 billion by 2030, highlighting the significant market opportunity.
India’s Cardiovascular Device Market Presents a Large Opportunity
India’s cardiovascular device market includes coronary intervention, peripheral intervention, neurovascular intervention, and structural heart devices. Globally, the cardiovascular device market is valued at around US$26 billion, while India’s vascular intervention market is expected to grow from US$355 million to US$505 million by 2029.
The coronary stent market is projected to expand from US$249 million to US$342 million by 2029, supported by rising adoption of drug-eluting stents (DES). Meanwhile, the structural heart device market is expected to grow from US$39.7 million in 2024 to US$121.5 million by 2029, driven by increasing TAVI procedures. These fast-growing segments provide a significant long-term opportunity for S3V Vascular Technologies (S3V Unlisted shares).
How S3V Is Building an End-to-End Cardiovascular and Neurovascular Portfolio
S3V Vascular Technologies is expanding beyond coronary stents, PTCA balloons, and peripheral vascular devices by developing an integrated cardiovascular and neurovascular product portfolio. Its pipeline includes a balloon-expandable TAVR platform and indigenous neurovascular products such as microcatheters, aspiration catheters, neuro guidewires, and stent retrievers, which are currently dominated by global players.
To support this strategy, S3V is investing around ₹300 crore in an integrated neurovascular manufacturing facility. By producing critical components in-house instead of relying on imports, the company aims to reduce costs, improve manufacturing efficiency, and make advanced neurovascular treatments more affordable in India.
How S3V Compares With Other Indian Medical Device Companies
India’s cardiovascular device market is led by established players such as Meril Life Sciences and Sahajanand Medical Technologies (SMT), which offer broad product portfolios across coronary, peripheral, and structural heart devices. In comparison, S3V Vascular Technologies is still in the early stages, expanding beyond coronary and peripheral intervention into structural heart and neurovascular products currently under development.
India’s Stent Market Is Dominated by Established Players
The Indian drug-eluting stent (DES) market is dominated by SMT, with around 31% market share, followed by Meril Life Sciences (25–30%), Abbott (15–18%), Boston Scientific (8–10%), and Medtronic (6–8%). These companies have built strong positions through years of clinical validation, regulatory approvals, manufacturing scale, and physician relationships, making the market highly competitive for emerging players like S3V.
Peer to Peer Analysis :SMT vs Meril vs S3V
S3V remains significantly smaller than India’s leading MedTech companies. In FY25, S3V reported revenue of ₹13 crore, compared with ₹1,024 crore for SMT and ₹1,795 crore for Meril Life Sciences, highlighting the company’s early stage of growth.
SMT has also built large manufacturing capabilities, with annual capacity of around 840,000 coronary stents, 960,000 catheters, 7,800 TAVI valves, and 42,000 occluders. Its global presence is equally strong, with 32% of revenue coming from Europe and 35% from the Rest of the World, demonstrating how Indian MedTech companies can successfully scale into international regulated markets. If S3V executes its product pipeline successfully, it could also target both domestic and global opportunities over the long term.
Valuation: High Expectations Already Priced In
Despite its long-term opportunity, S3V Unlisted Shares trade at a premium valuation of around 52.8x EV/Revenue, significantly higher than global peers such as Medtronic (4–5x), Abbott (5–6x), Boston Scientific (6–7x), and Edwards Lifesciences (8–10x). At the current price of around ₹560 per share, investors are largely betting on successful product launches, regulatory approvals, and future revenue growth, making execution the key factor to watch.
Can S3V Become a Significant MedTech Player?
S3V is expanding beyond the highly competitive coronary stent market into neurovascular and TAVR devices, where domestic competition is relatively limited and entry barriers are higher. Unlike many peers, S3V is focusing on indigenous manufacturing. For comparison, SMT imported around ₹195 crore of components in FY25, nearly 73% of its total purchases, while S3V aims to manufacture critical components in-house. If successful, this strategy could reduce costs, support import substitution, and strengthen its long-term growth potential.
Conclusion
India’s MedTech industry offers significant long-term growth opportunities, supported by rising healthcare demand, import substitution, and expanding cardiovascular care. S3V Vascular Technologies is positioning itself through indigenous manufacturing and a diversified product pipeline. However, given its early stage and premium valuation, the company’s future will largely depend on successful execution and regulatory approvals.
Why Choose Unlisted Network?
Investing in unlisted shares and pre-IPO companies requires more than just access—it requires reliable research, transparent pricing, and a trustworthy transaction process. At Unlisted Network, we empower investors with data-driven insights and comprehensive company analysis, helping them evaluate opportunities with greater confidence.
- Transparent Pricing: Zero hidden markups with clear and competitive pricing.
- Secure Transactions: SEBI-compliant processes, escrow-based settlements, and complete documentation.
- Access to Exclusive Opportunities: Explore unlisted shares, pre-IPO companies, startup ESOPs, and other private market investments.
- Research-Driven Analysis: Detailed financial analysis, valuation comparisons, industry insights, and risk assessments designed to help investors make informed decisions.
Whether you’re researching S3V Vascular Technologies Unlisted Shares, tracking the latest S3V Unlisted Share Price, or exploring other promising pre-IPO investment opportunities, Unlisted Network provides the research, transparency, and market intelligence needed to navigate India’s private equity markets
Disclaimer: This article is for informational and educational purposes only and should not be construed as investment advice or a recommendation to buy or sell any security. Investments in unlisted shares and IPOs involve risks. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.